Recce Pharmaceuticals (RCE) Short Interest
Recce Pharmaceuticals (ASX:RCE) had 0.00% of shares reported as short positions as of 17 Aug 2026, representing 480 shares. Recce Pharmaceuticals operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Recce Pharmaceuticals
Recce Pharmaceuticals Ltd is an Australian pharmaceutical company focused on developing a new class of synthetic anti-infectives to combat antibiotic-resistant superbugs. Their lead candidate, RECCE® 327, has received Qualified Infectious Disease Product (QIDP) designation from the FDA, offering potential market exclusivity. The company aims to provide effective treatments against a broad range of bacteria and viral indications.
Short position
Recce Pharmaceuticals (ASX:RCE) has 0.00% of its shares on issue reported as short positions as of 17 Aug 2026, or about 480 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.36% in August 2021. RCE is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4RCE intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Recce Pharmaceuticals
Latest RCE news
All news- Recce Pharmaceuticals Expands Phase 3 Diabetic Foot Trial With Comparator Arm
smallcaps
- Recce approval has R327G go head-to-head with antibiotic treatments
stockhead
- HREC Approves Comparator Study for Pivotal Phase 3 DFI
asx
- Change of Director's Interest Notices (x4)
asx
- Recce Pharmaceuticals Files Cleansing Notice After Issuing 250,000 Shares on July 31, 2026
kalkine
About
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss RCE
Start a research thread or post the first pulse update